NCT06113731View on ClinicalTrials.gov

A PhaseⅡ Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine

PHASE2RecruitingINTERVENTIONAL
Enrollment

980

Participants

Timeline

Start Date

July 10, 2023

Primary Completion Date

October 30, 2023

Study Completion Date

October 31, 2024

Conditions
SARS-CoV-2 Infection
Interventions
BIOLOGICAL

COVID-19 mRNA Vaccine (ZSVG-02-O)

30 μg

BIOLOGICAL

COVID-19 mRNA Vaccine (ZSVG-02-O)

60 μg

BIOLOGICAL

COVID-19 Vaccine (Vero Cell) ,Inactivated

COVILO

Trial Locations (2)

Unknown

RECRUITING

Dengfeng Centre for Disease Control and Prevention and Control, Songyang

RECRUITING

Henan Provincial Centre for Disease Control and Prevention, Zhengzhou

All Listed Sponsors
lead

CNBG-Virogin Biotech (Shanghai) Ltd.

INDUSTRY